September 18, 2020

The Niche

Knoepfler lab stem cell blog

Search Results for: ips cell

3 min read

We’ve had another week of interesting stem cell news and papers. Here is an aggregate of the stem cell and regenerative medicine week that was. Stem cell therapy for baldness I’ve covered stem cells for hair loss for about a decade here on The Niche. While it seems like it’s taken a long time for this work to advance, there has been concrete progress. From Nature News, Regenerative medicine could pave the way to treating baldness. Here’s the actual Nature paper in question: Hair-bearing human …Read More

2 min read

Where do things stand today in 2020 with IPS cell research? It’s been 14 years since they were first reported, but they continue to make news. Back in 2006 I was wrapping up my postdoc with Bob Eisenman at The Hutch in Seattle, largely studying Myc, when Shinya Yamanaka published his first induced pluripotent stem cell (IPS cell) paper in Cell. For me it was one of those amazing moments reading a pub when you just go “wow!” Now all these years later we …Read More

3 min read

The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss among people age 65 and …Read More

2 min read

Once or twice a month I do a post on notable stem cell publications and news, which often but not always include research on iPS cells. It’s sort of a recommended reads kind of post, but I often include one or two things that aren’t necessarily recommended exactly yet seem kind of surprising or novel in some ways. Here’s today’s list. One bit of news first On the RMAT front: “FDA Grants RMAT Designation for CAR T-Cell Therapy for Multiple Myeloma.”  You can see …Read More